Estrogen receptor (ER), progesterone receptor (PR), and HER2 expression are used as molecular markers to stratify patients within specific BC subtypes for treatment and prognosis, but this does not entirely reflect the molecular heterogeneity and complexity of the disease. This evidence concerns the gene ERBB2 and breast cancer.